Slide 1: Alembic Pharmaceuticals Limited Investor Presentation Q2 FY26
Alembic Pharmaceuticals Limited Investor Presentation Q2 FY26
Slide 2: Safe Harbour Statement
Safe Harbour Statement The materials and information presented herein may include forward looking statements , which reflect current expectations, projections, and assumptions. These statements are inherently subject to risks and uncertainties that could cause actual results or outcomes to differ ma
Slide 3: Quarterly Snapshot
Quarterly Snapshot Key Highlights Revenue INR 19.10 Bn India Branded Business +16% YoY Achieved a 5% YoY growth with quarterly revenues of INR 6.39 billion. US Generics EBIDTA INR 3.24 Bn Reported a 21% YoY increase driven by key product launches and market share +26% YoY EBIDTA Margin ~17% gains in
Slide 4: Revenue Summary
Revenue Summary INR Bn Business Q2 FY26 Q2 FY25 Y-o-Y Q1 FY26 Q-o-Q H1 FY26 H1 FY25 Y-o-Y Formulations India Branded Business 6.39 6.09 5% 5.99 6% 12.38 11.81 5% US Generics 5.66 4.67 21% 5.23 8% 10.89 9.28 17% Ex-US Generics 3.92 2.98 31% 3.28 16% 7.19 5.68 27% API 3.14 2.74 15% 2.61 17% 5.75 5.32
Slide 5: India Branded Business – Performance
India Branded Business – Performance Revenue Q2 FY26 Revenue in Past 5 Years CAGR: 12% INR Bn 23.39 6.39 22.00 6.09 20.63 19.26 19% 22% 14.96 Animal Health 28% 28% Acute 53% 51% Specialty Q2FY25 Q2FY26 FY21 FY22 FY23 FY24 FY25 Sales Mix Q2 FY26 > The India Branded Business recorded 5% growth with re
Slide 6: India Branded Business – Rx Driven Rankings
India Branded Business – Rx Driven Rankings Top Brands with Rank and Market Share Driving Overall Prescription Business BRANDS Rank MS% Q2 BRANDS Rank MS% 133.2 Q2 FY 26* Q2 Q2 128.7 FY 26* FY 26* FY 26* 0.24 0.23 AZITHRAL 1 30.2 WIKORYL 3 10.4 ALTHROCIN 1 86.3 BROZEET-LS 3 6.7 CRINA-NCR 1 29.9 ISOF
Slide 7: Animal Health Business
Animal Health Business Revenue Q2 FY26 Growth: 17% INR Mn Revenue in Past 5 Years CAGR: 24% INR Mn 1380 Billions 4305 3553 2860 2320 1180 1841 Q2FY25 Q2FY26 FY21 FY22 FY23 FY24 FY25 Sales Mix Q2 FY26 > Alembic operates in the Livestock, Poultry, and Companion Animal Antibiotic segments. > Market lea
Slide 8: US Generics Business
US Generics Business Revenue Q2 FY26 Growth: 21% INR Bn Revenue in Past 5 Years INR Bn 21.63 19.57 17.30 5.66 16.66 15.72 4.67 Q2FY25 Q2FY26 FY21 FY22 FY23 FY24 FY25 Approved ANDAs > Well-established US front-end with a strong customer base. Total 226* * Includes 21 Tentative Approvals > 7 products
Slide 9: Ex-US Generics Business
Ex-US Generics Business Revenue Q2 FY26 Growth: 31% INR Bn Revenue in past 5 Years CAGR: 12% INR Bn 3.92 12.43 2.98 10.52 8.52 7.75 Q2FY25 Q2FY26 7.79 > Achieved 31% YoY growth in Q2, momentum sustained globally through targeted execution and strong customer demand. > Key partnerships active in Euro
Slide 10: API Business
API Business Revenue Q2 FY26 Revenue in past 5 Years Growth: 15% INR Bn CAGR: 4% INR Bn 12.46 3.14 11.66 11.33 2.74 9.55 9.39 Q2FY25 Q2FY26 > Growth of 15% on annual basis is led by surge in volumes, partially offset by price erosion across the markets. > 1 US DMF filed in Q2 FY26. 141 Cumulative DM
Slide 11: R&D Dosage Form-wise ANDA Approval and Launch – H1 FY26
R&D Dosage Form-wise ANDA Approval and Launch – H1 FY26 Continued investment in building product pipelines INR Bn Approval 8 7 15.8% Launched 14.0% 6 12.8% 4 7.8% 4 7.6% R&D Spend 2 2 8.4 2 1 1 1 1 7.2 R&D % of sales 6.7 4.8 5.2 0 OSD OSD-Onco Injectables Injectables-Onco Opthalmology Derma Approved
Slide 12: Q2 Financials Summary – Profit & Loss statement
Q2 Financials Summary – Profit & Loss statement INR Bn Particulars Q-2 FY25 Q-1 FY26 Q-2 FY26 YoY(%) QoQ(%) H-1 FY 25 H-1 FY 26 YoY(%) Revenue from Operations 16.48 17.11 19.10 16% 12% 32.10 36.21 13% Other Income 0.17 0.07 0.07 0.19 0.13 -29% Total Income 16.65 17.17 19.17 15% 12% 32.29 36.34 13% M
Slide 13: Q2 Financials Summary – Balance sheet
Q2 Financials Summary – Balance sheet INR Bn As at 31st March, As at 30th Particulars 2025 September, 2025 Non-current assets Property, plant and equipment 25.24 26.12 Capital work-in-progress 8.37 9.03 Other Intangible assets 0.00 2.22 Financial Assets 1.27 1.29 Deferred tax assets 1.66 1.65 Other
Slide 14: Yearly Financials
Yearly Financials INR Bn Revenue EBIDTA Net Profit 6.65 10.53 10.53 6.16 66.72 9.61 # 5.84 62.29 56.53 4.97 # 53.06 7.79 # FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 FY22 FY23 FY24 FY25 EBIDTA margin % Capex ROCE % 20% 5.75 25% * 16% 4.67 14% # 15% # 4.12 3.45 15% *# 16%*# 14%*# FY22 FY23 FY24 FY25 FY2
Slide 15: Sustainability – Alembic's ESG Targets
Sustainability >A l e m b i c ’ s E S G Ta r g e t s Net Zero by 2050 • 63% GHG Emission reduction by 2034 Water Neutrality by 2027 50,000 trees by 2027 • 90% GHG Emission reduction by 2050 (Approved by SBTi) Environment Social Governance • We are one of the 10 Indian Pharma companies with approved
Slide 16: Company Overview
Company Overview Alembic Pharmaceuticals Ltd. Investor Presentation Q2 FY26
Slide 17: Company at a Glance
Company at a Glance Mission Team Size ANDA Filings R&D Centers Manufacturing Facilities Improve Healthcare with 16,500+ 269 (Sep 30,2025) 2 10 innovation, commitment and Trust Prescribers in India Field Force Brands Net Zero Target Products in the USA 2,44,000 5,500+ 207 2050 170 Alembic Pharmaceuti
Slide 18: Value Proposition
Value Proposition Developing a specialty drug Supplying APIs to 60+ countries pipeline for India globally Established presence in Chile & Exploring opportunities in UAE Injectables Ranks 20th in the Indian Expanding product portfolio in the formulations market USA Consistent, high dividend payout St
Slide 19: The Journey
The Journey 2012 Formed a JV, Rhizen , for 2025 2006 Indore facility NCE Research FDA- Commissioned 2007 & approved API facility Acquired Acquired Utility Dabur’s Indian Therapeutics Cardiology, GI & 2013 Limited 1907 Gynecology 2010 Launched first 2013 2023 brands NDA with a Established by Pharmace
Slide 20: Robust Infrastructure
Robust Infrastructure Product brand logo Dosage Form Last USFDA Audit International Generics F1 - Panelav General Oral Solids July’24 F2 - Panelav Oncology Oral Solids Mar’24 Oncology Injectables Oct’24 F3 - Karkhadi General Injectables Mar’23 Ophthalmic F2 - Panelav F3 - Karkhadi F4 - Jarod General
Slide 21: Thank You
Thank You For further queries, please contact: Investor Relations Advisors Mr. Ajay Desai Adfactors PR Pvt. Ltd. ajay.desai@alembic.co.in 022-6695 3681 Snighter Albuquerque snighter.a@adfactorspr.com Darshan Mankad darshan.mankad@adfactorspr.com 2nd Floor, Prime Corporate Park Sahar Road, Andheri Ea